GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » Net Income

YBGJ (Yubo International Biotech) Net Income : $-1.45 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Yubo International Biotech's Net Income for the three months ended in Jun. 2024 was $-0.53 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.45 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Yubo International Biotech's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $-0.00.


Yubo International Biotech Net Income Historical Data

The historical data trend for Yubo International Biotech's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech Net Income Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income
-0.71 -1.54 -1.21 -1.20

Yubo International Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 0.01 -0.52 -0.41 -0.53

Yubo International Biotech Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Yubo International Biotech's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.195+0+0+0
=-1.20

Yubo International Biotech's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.598+0+0+0.07
=-0.53

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yubo International Biotech  (OTCPK:YBGJ) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Yubo International Biotech's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Yubo International Biotech Net Income Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Yubo International Biotech Business Description

Traded in Other Exchanges
N/A
Address
31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.
Executives
Lina Liu 10 percent owner, officer: CFO, Treasurer and Secretary MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui director MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun director, officer: President and CEO MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth director C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc 10 percent owner 8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica officer: Treasurer and Secretary C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff director, officer: Chairman, President, CSO C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman director C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler director C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech Headlines

No Headlines